Sign In
Buy NVCR
$16.09
-0.210 (-1.29%)
At Close: Jul 13, 2026
NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026
03:01pm, Friday, 10'th Jul 2026
NovoCure Limited is downgraded from Strong Buy to Buy after the phase 3 TRIDENT trial failed to meet its primary endpoint of OS in newly diagnosed GBM patients. Company maintains growth potential with
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
05:40pm, Thursday, 09'th Jul 2026
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to co
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
05:57pm, Tuesday, 07'th Jul 2026
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are ad
NovoCure's Cancer Treatment Device Option Pax Gets European Approval
02:01pm, Wednesday, 01'st Jul 2026
NVCR secures European approval for Optune Pax, expanding access to its pancreatic cancer treatment after strong late-stage trial results.
Novocure to Report Second Quarter 2026 Financial Results
07:00am, Wednesday, 01'st Jul 2026
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
05:16pm, Tuesday, 30'th Jun 2026
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are ad
Novocure's Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
07:00am, Tuesday, 30'th Jun 2026
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced p
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
07:36pm, Thursday, 25'th Jun 2026
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to con
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
02:45pm, Wednesday, 24'th Jun 2026
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
10:39am, Monday, 22'nd Jun 2026
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
02:00pm, Saturday, 20'th Jun 2026
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure L
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
01:34pm, Saturday, 20'th Jun 2026
LOS ANGELES--(BUSINESS WIRE)---- $NVCR--NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm.
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
12:50pm, Friday, 19'th Jun 2026
Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-to-patient model for tumor treatment, targeting niche
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
09:41pm, Thursday, 18'th Jun 2026
Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday
Novocure's cancer treatment fails to meet late-stage trial goal
07:08am, Thursday, 18'th Jun 2026
Novocure said on Thursday that its cancer treatment for newly diagnosed brain tumors did not meet the main goal of a late-stage study.
